FDA Official Peter Marks Says FDA Likely Leaning Towards Xbb.1.5 As Strain For Updated 2023-24 Covid-19 Vaccines
Portfolio Pulse from Benzinga Newsdesk
FDA official Peter Marks announced that the FDA is likely leaning towards Xbb.1.5 as the strain for updated 2023-24 Covid-19 vaccines.
June 15, 2023 | 8:22 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AstraZeneca may need to update its Covid-19 vaccine for the Xbb.1.5 strain in 2023-24.
The FDA's leaning towards the Xbb.1.5 strain for updated Covid-19 vaccines may require AstraZeneca to update its vaccine. However, the impact on the stock price is uncertain as it depends on the company's ability to adapt and the market demand for the updated vaccine.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 50
NEUTRAL IMPACT
BioNTech may need to update its Covid-19 vaccine for the Xbb.1.5 strain in 2023-24.
The FDA's leaning towards the Xbb.1.5 strain for updated Covid-19 vaccines may require BioNTech to update its vaccine. However, the impact on the stock price is uncertain as it depends on the company's ability to adapt and the market demand for the updated vaccine.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 50
NEUTRAL IMPACT
Johnson & Johnson may need to update its Covid-19 vaccine for the Xbb.1.5 strain in 2023-24.
The FDA's leaning towards the Xbb.1.5 strain for updated Covid-19 vaccines may require Johnson & Johnson to update its vaccine. However, the impact on the stock price is uncertain as it depends on the company's ability to adapt and the market demand for the updated vaccine.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 50
NEUTRAL IMPACT
Moderna may need to update its Covid-19 vaccine for the Xbb.1.5 strain in 2023-24.
The FDA's leaning towards the Xbb.1.5 strain for updated Covid-19 vaccines may require Moderna to update its vaccine. However, the impact on the stock price is uncertain as it depends on the company's ability to adapt and the market demand for the updated vaccine.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 50
NEUTRAL IMPACT
Novavax may need to update its Covid-19 vaccine for the Xbb.1.5 strain in 2023-24.
The FDA's leaning towards the Xbb.1.5 strain for updated Covid-19 vaccines may require Novavax to update its vaccine. However, the impact on the stock price is uncertain as it depends on the company's ability to adapt and the market demand for the updated vaccine.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 50
NEUTRAL IMPACT
Pfizer may need to update its Covid-19 vaccine for the Xbb.1.5 strain in 2023-24.
The FDA's leaning towards the Xbb.1.5 strain for updated Covid-19 vaccines may require Pfizer to update its vaccine. However, the impact on the stock price is uncertain as it depends on the company's ability to adapt and the market demand for the updated vaccine.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 50